New Clinical Study Shows Masimo Corporation Rainbow SET(R) Pulse CO-Oximetry(TM) Provides Accurate Noninvasive Measurements of Hemoglobin in Pediatric Patients

IRVINE, Calif., March 24 /PRNewswire-FirstCall/ -- Masimo (Nasdaq:MASI - News), the inventor of Pulse CO-Oximetry™ and Measure-Through Motion and Low Perfusion pulse oximetry, announced today that a new clinical study presented this week at the IARS Annual Meeting in Honolulu, Hawaii, demonstrates that noninvasive and continuous hemoglobin (SpHb) from Masimo Rainbow SET Pulse CO-Oximetry provides comparable accuracy as point-of-care invasive measurements of total hemoglobin versus standard laboratory invasive measurements of total hemoglobin. The study confirms that SpHb is accurate, reliable, and a clinically-acceptable alternative for monitoring hemoglobin, and is the first SpHb study presented in pediatric patients.
MORE ON THIS TOPIC